Connect your AI

Glaukos GKOS Tax on Share Settlement

Tax on Share Settlement at other companies

Regeneron PharmaceuticalsREGN

$73.2M+1,602%

ExelixisEXEL

$34.23M+52.0%

Other financials

Income statement

Revenue$150.6M+41.2%

Gross profit$117.2M+42.4%

Operating income-$19.9M+4.0%

Net income-$19.8M-9.0%

EPS (diluted)-$0.34-6.3%

Balance sheet

Cash & equivalents$104.2M-8.8%

Total debt$105.9M-1.7%

Total equity$670.9M-12.2%

Total assets$893.3M-7.5%

Cash flow

Operating cash flow-$12.5M+32.4%

CapEx$4.0M+104%

Free cash flow-$16.5M+19.4%

Valuation

Market cap$7.68B+12.3%

Enterprise value$7.68B+12.5%

P/S13.9×-3.0×

Profitability

Gross margin78.1%+2.3pp

Operating margin-36.1%+24.3pp

Net margin-34.3%+4.8pp

FCF margin-13.2%-3.9pp

Returns & leverage

Return on equity-26.4%+11.1pp

Debt / equity0.2×0.0×

Current ratio5.4×-1.1×

Where this comes from

Reported directly by Glaukos in its filing.

Tagged under the XBRL concept us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation.

The official record: Glaukos’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Glaukos's tax on share settlement.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Glaukos's tax on share settlement?: Glaukos (GKOS) reported tax on share settlement of $5.64M in Q1 2026.
How has Glaukos's tax on share settlement changed year-over-year?: Glaukos's tax on share settlement increased by 16.4% year-over-year, from $4.85M to $5.64M.
What is the long-term trend for Glaukos's tax on share settlement?: Over 3 years (2021 to 2025), Glaukos's tax on share settlement has grown at a 30.1% compound annual growth rate (CAGR), from $3.69M to $8.13M.
What does tax on share settlement mean?: Cash paid to tax authorities for employee share vesting, where the company withholds shares and pays the tax obligation in cash.